A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Running, not enrolling · Phase 3

Conditions studied: Relapsed or Refractory Multiple Myeloma

In brief

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Key facts

Study ID

NCT05552976

Run by

Bristol-Myers Squibb

People needed

606

Starts

2023-01-10

Expected to finish

2029-07-25

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.
• i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.
• ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.
• iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.
• Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).
• Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible).
• Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
• Participant must have documented disease progression during or after their last antimyeloma regimen.

You may not qualify if…

• Participant who has had prior treatment with mezigdomide or carfilzomib.
• Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Local Institution - 0289 — Annapolis, Maryland, United States
• Local Institution - 0204 — Boston, Massachusetts, United States
• Local Institution - 0046 — Mobile, Alabama, United States
• Local Institution - 0005 — Cerritos, California, United States
• Local Institution - 0190 — Irvine, California, United States
• Local Institution - 0187 — Los Angeles, California, United States
• Local Institution - 0344 — Santa Rosa, California, United States
• Local Institution - 0339 — Stockton, California, United States
• Local Institution - 0279 — Newark, Delaware, United States
• Local Institution - 0341 — Fort Myers, Florida, United States
• Local Institution - 0342 — St. Petersburg, Florida, United States
• Local Institution - 0340 — West Palm Beach, Florida, United States
• Local Institution - 0348 — Atlanta, Georgia, United States
• Local Institution - 0291 — Atlanta, Georgia, United States
• Local Institution - 0346 — Minneapolis, Minnesota, United States
• Local Institution - 0222 — Little Silver, New Jersey, United States
• Local Institution - 0199 — The Bronx, New York, United States
• Local Institution - 0322 — Cleveland, Ohio, United States
• Local Institution - 0172 — Columbus, Ohio, United States
• Local Institution - 0321 — Providence, Rhode Island, United States
• Local Institution - 0338 — Greer, South Carolina, United States
• Local Institution - 0349 — Chattanooga, Tennessee, United States
• Local Institution - 0323 — Nashville, Tennessee, United States
• Local Institution - 0337 — Fort Worth, Texas, United States
• Saint Alphonsus Regional Medical Center — Boise, Idaho, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.